AQR Capital Management
CADL icon

AQR Capital Management’s Candel Therapeutics CADL Stock Holding History

AQR Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.3K Buy
+18,028
New +$98.1K ﹤0.01% 3691
2025
Q3 		– Sell
-19,261
Closed -$97.5K – 3482
2025
Q2 		$97.5K Sell
19,261
-1,757
-8% -$9.04K ﹤0.01% 3180
2025
Q1 		$119K Sell
21,018
-841
-4% -$6.87K ﹤0.01% 2985
2024
Q4 		$190K Buy
21,859
+1,823
+9% +$10.8K ﹤0.01% 2681
2024
Q3 		$139K Buy
+20,036
New +$124K ﹤0.01% 2623

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's CADL Position: Q1 2026 in Review

AQR Capital Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 18,028 shares worth $88.3K. The stake represents ﹤0.01% of the portfolio and ranks #3691 among its holdings. This is a return to the name: AQR Capital Management previously reported a position in CADL as recently as Q2 2025.

AQR Capital Management first reported a position in CADL in Q3 2024 and has held it in 5 quarters since. The position peaked at $190K in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • AQR Capital Management held 18,028 shares of Candel Therapeutics worth $88.3K as of Q1 2026.
  • Candel Therapeutics was a new AQR Capital Management position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3691 holding.
  • AQR Capital Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • AQR Capital Management's Candel Therapeutics position peaked at $190K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.